Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.

Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.

Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Sakura Finetek launches laser cassette printer

September 2024—Sakura Finetek Europe announced the launch of the Tissue-Tek xPrint LP laser cassette printer. Features of the laser printer include high-definition barcode printing at 2,500 dpi and a printing speed of up to 2.5 seconds per cassette. It is designed to print on Tissue-Tek Paraform cassettes of any color, without the need for calibration or additional setup. Print quality is robust and resistant to heat, alcohol, xylene, acid, and scratching, as well as other common laboratory conditions. The printer supports a wide range of content, including logos, barcodes, QR codes, data matrices, and text that can be displayed in the Windows system.

FDA approves Illumina cancer biomarker test plus two CDxs

September 2024—Illumina announced Food and Drug Administration approval of its in vitro diagnostic TruSight Oncology Comprehensive test and its first two companion diagnostic indications. This single test interrogates more than 500 genes to profile a patient’s solid tumor, helping to increase the likelihood of identifying an immuno-oncology biomarker or clinically actionable biomarkers that enable targeted therapy options or clinical trial enrollment.

Enzyme calibration verifiers for creatine kinase testing

September 2024—Verichem Laboratories now offers multilevel calibration verification materials for creatine kinase activity as part of its liquid-stable, ready-to-use Enzyme ER Verifier kit. The calibration verifiers are intended to be treated as patient specimens and are available for use on a variety of wet clinical chemistry systems, including from Beckman Coulter, Abbott, Siemens Healthineers, and Roche. The kit contains 5 mL of material for each of the six levels and is stable for 18 months from the manufacturing date.

Thermo Fisher, NCI partner on myeloMATCH umbrella trial

September 2024—Thermo Fisher Scientific is partnering with the National Cancer Institute on the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial to help accelerate research into new treatments for acute myeloid leukemia and myelodysplastic syndrome. The study involves testing patients’ bone marrow and blood for certain genetic biomarkers using Thermo Fisher’s next-generation sequencing technology so clinical sites can more quickly match patients with an appropriate clinical trial that tests a treatment designed to target specific mutations present in the samples.

FDA approves Guardant Shield blood test for CRC

September 2024—Guardant Health announced FDA approval of the company’s Shield blood test for colorectal cancer screening in adults who are 45 and older and at average risk for the disease. It is the first blood test to be approved by the FDA as a primary screening option for CRC and that meets performance requirements for Medicare coverage.

BioPorto unveils FDA-cleared NGAL test for pediatric use

August 2024—BioPorto Diagnostics unveiled its ProNephro AKI (NGAL) test at ADLM 2024, July 28–Aug. 1, in Chicago. The FDA 510(k)-cleared test is the first acute kidney injury biomarker test cleared for pediatric use (ages 3 months through 21 years) in the United States.

Horiba launches Yumizen H550 range with ESR and CBC/diff

August 2024—Horiba announced that it has expanded its compact hematology instrument range with the launch of three models now with erythrocyte sedimentation rate onboard. The Yumizen H550E (autoloader), H500E CT (closed tube), and H500E OT (open tube) offer combined testing for CBC with differential and ESR results from whole blood in 60 seconds.

Machaon releases updated HLH genetic panel

August 2024—Machaon Diagnostics has updated its genetic panel for detecting hemophagocytic lymphohistiocytosis. The HLH genetic panel 3.0 sequences 32 genes to reflect the most current understanding of HLH in the scientific literature and includes UNC13D inversion. The panel has a turnaround time of 48 hours. Draw kits are available.

Bio-Rad launches GBS positive, negative controls

August 2024—Bio-Rad Laboratories has launched its Exact Diagnostics GBS positive and negative run controls. The independent quality controls are intended to be used with group B streptococcus molecular assays for evaluating assay performance and testing operator proficiency.

Sysmex America names Dan Zortman as new CEO

August 2024—Sysmex America announced on July 9 that longtime health care executive Dan Zortman has been named the company’s new CEO. Andy Hay, who has served as CEO since 2021, will continue to serve as chairman and president of Sysmex America with a focus on the company’s emerging Hinotori surgical robotic system business.

MARKETPLACE

TRENDING